Bone Abstracts

Drug treatment for osteoporosis typically begins with an oral bisphosphonate, regardless of initial BMD or fracture risk and decisions to continue or change treatment are often based on evidence of ‘response’ to treatment based on changes in BMD, bone turnover markers, and occurrence of fractures. Treatment is often continued for fixed periods of time, perhaps stopped for a ‘drug holiday’.This approach differs from preventive therapy ...

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...

Purpose: To test whether bisphosphonates for osteoporosis reduce the risk of breast cancer.Background: Observational studies and meta-analyses find that women taking bisphosphonates have about a 1/3rd reduction in risk of breast cancer as soon as 1 year of treatment. This is plausible because bisphosphonates have in vitro anti-tumor activity and high doses of zoledronate reduce recurrence in women with breast cancer. However, observational studi...